Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Net Cash Flow (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Net Cash Flow for 7 consecutive years, with $27.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 49.39% to $27.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.5 million, a 107.45% increase, with the full-year FY2025 number at $11.5 million, up 107.45% from a year prior.
  • Net Cash Flow was $27.0 million for Q4 2025 at Beam Therapeutics, up from -$14.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $400.0 million in Q3 2021 to a low of -$263.2 million in Q1 2022.
  • A 5-year average of $6.2 million and a median of -$16.4 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 15444.12% in 2021, then crashed 5422.76% in 2025.
  • Beam Therapeutics' Net Cash Flow stood at -$54.1 million in 2021, then soared by 240.9% to $76.3 million in 2022, then surged by 249.97% to $266.9 million in 2023, then plummeted by 80.01% to $53.4 million in 2024, then plummeted by 49.39% to $27.0 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Net Cash Flow are $27.0 million (Q4 2025), -$14.1 million (Q3 2025), and -$245.8 million (Q2 2025).